TLDR
- AbbVie stock gained 1.17% to $266.27 after RINVOQ secured major EU approval.
- The approval covers adults and adolescents aged 12 and older with severe AA.
- Phase 3 studies showed significant scalp hair regrowth after 24 weeks of use.
- Both RINVOQ doses met key efficacy goals across two controlled Phase 3 studies.
- The decision expands AbbVie’s immunology portfolio and commercial reach in Europe.
AbbVie (ABBV) stock rose 1.17% to $266.27 after European regulators approved RINVOQ for severe alopecia areata. The decision expands AbbVie’s immunology portfolio across adult and adolescent patients in the European Union. It also gives eligible patients another treatment option for a difficult autoimmune hair-loss disorder.
EU Approval Expands RINVOQ Use
The European Commission approved once-daily RINVOQ doses of 15 milligrams and 30 milligrams. The approval covers adults and adolescents aged 12 years and older with severe alopecia areata. AbbVie secured the decision after presenting evidence from its ongoing Phase 3 UP-AA clinical program.
The new indication strengthens RINVOQ’s role across several immune-mediated diseases in Europe. EU regulators already authorize the therapy for conditions including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. They also allow its use for atopic dermatitis, vitiligo, psoriatic arthritis, and axial spondylarthritis.
AbbVie developed RINVOQ as an oral therapy that targets immune pathways linked to inflammatory diseases. The company continues to expand the drug across dermatology, gastroenterology, and rheumatology markets. That strategy supports AbbVie’s effort to offset pressure from competition facing older medicines.
Phase 3 Data Support Hair Regrowth
The UP-AA program includes two randomized, placebo-controlled, double-blind Phase 3 studies. Researchers tested both approved doses in adults and adolescents with severe alopecia areata. Each study measured scalp hair coverage after 24 weeks of treatment.
Both doses met the primary endpoint in each study at week 24. More treated patients achieved at least 80% scalp hair coverage than placebo recipients. The studies also recorded complete scalp hair regrowth among some patients receiving RINVOQ.
Researchers reported improvements in eyebrow and eyelash growth during the same treatment period. AbbVie said the safety results matched findings from other approved RINVOQ uses. The company continues to collect longer-term efficacy and safety data through the ongoing program.
Alopecia Areata Adds Major Disease Burden
Alopecia areata causes the immune system to attack hair follicles across the body. The disease can create small bald patches or complete loss of scalp and body hair. Its unpredictable course often creates lasting physical, social, and emotional pressure.
Studies link alopecia areata with higher rates of new depression and anxiety diagnoses. The condition often carries added stigma because many people wrongly view it as cosmetic. Severe cases can disrupt work, relationships, confidence, and daily routines.
The approval gives AbbVie access to another segment of Europe’s dermatology market. It also expands RINVOQ’s commercial reach while strengthening the company’s immunology growth strategy. AbbVie stock finished higher as the market absorbed the regulatory update and its potential sales impact.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
